#MolecularDiagnostics

[athenese-dx]

𝗔𝘁𝗵𝗲𝗻𝗲𝘀𝗲-𝗗𝘅'𝘀 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗥𝗮𝗻𝗴𝗲𝘀!

Athenese-Dx MolDx ranges are engineered for precision, accuracy, and reliability. Our comprehensive suite includes:

1. DNA/RNA Extraction Kits – High-yield & pure nucleic acid extraction 2. Nucleic Acid Extractor – Automated, fast, and efficient workflow

𝗥𝗲𝗮𝗹-𝗧𝗶𝗺𝗲 𝗣𝗖𝗥 𝗞𝗶𝘁𝘀:

1. HBV & HCV (Quantitative) – Accurate viral load detection 2. Typhoid & Leptospira (Qualitative) – Rapid & reliable pathogen identification

Watch the video to learn more.

Visit → https://athenesedx.com/product-category/molecular-pcr-kits/

AtheneseDx #PCRKits #MolecularDiagnostics #IVD #India #PCR #RealTimePCR #NewProductLaunch #LaboratoryExcellence #DiagnosticSolutions #Diagnostics #Pathology #Medical #Medicine #Practitioner #ClinicalDiagnostics #ClinicalChemistry #ELISA #RapidTest #ClinicalLaboratory #RTPCR #Healthcare #InVitroDiagnostics #LabSupplies #LaboratorySupplies #DiagnosticKits

[skyquesttinsights]

Companion Diagnostics Market Size, Share, and Growth Rate: A Look Ahead to 2032

The companion diagnostics market is a rapidly evolving segment of the healthcare industry, driven by advancements in personalized medicine and the growing need for targeted therapies. Companion diagnostics (CDx) are essential tools that help identify the appropriate patients for specific treatments, enhancing therapeutic efficacy and minimizing adverse effects. As the healthcare landscape continues to shift towards personalized medicine, the companion diagnostics market is poised for significant growth over the next decade.

As of 2024, the global companion diagnostics market was valued at approximately $7.76 billion. This market is expected to grow at a compound annual growth rate (CAGR) of around 12.5% from 2025 to 2032, potentially reaching $19.92 billion by the end of the forecast period. The increasing prevalence of chronic diseases, advancements in genomics, and the rising demand for personalized medicine are major factors driving this growth.

Request a Free Sample Copy - https://www.skyquestt.com/sample-request/companion-diagnostics-market

Key Market Segments

1. Technology Type

   - Polymerase Chain Reaction (PCR)

   - In Situ Hybridization (ISH)

   - Next-Generation Sequencing (NGS)

   - Immunohistochemistry (IHC)

2. Application

   - Oncology

   - Cardiovascular Diseases

   - Infectious Diseases

   - Neurological Disorders

3. End-User

   - Pharmaceutical Companies

   - Clinical Laboratories

   - Research Institutions

Regional Insights

North America currently holds the largest share of the companion diagnostics market, driven by a robust healthcare infrastructure, high levels of investment in R&D, and favorable reimbursement policies.

Europe follows closely, with significant contributions from countries like Germany and the UK.

The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by increasing healthcare expenditures, rising awareness of personalized medicine, and expanding pharmaceutical sectors.

Top Player’s Company Profiles

Abbott (United States)

IDVet (France) 

F. Hoffmann-La Roche Ltd. (Switzerland) 

Agilent Technologies, Inc. (United States) 

AniCell Biotech (United States) 

Illumina, Inc. (United States) 

Guardant Health (United States) 

Thermo Fisher Scientific Inc. (United States) 

BIOMERIEUX (France) 

NEOGEN Corporation (United States) 

Zoetis Inc. (United States) 

Myriad Genetics, Inc. (United States) 

Virbac SA (France)

Take Action Now: Secure Your Companion Diagnostics Market Today - https://www.skyquestt.com/buy-now/companion-diagnostics-market

Growth Drivers

1. Rising Demand for Personalized Medicine: The shift from traditional one-size-fits-all treatments to personalized approaches are a significant driver of the companion diagnostics market. By identifying specific biomarkers, companion diagnostics enable tailored treatment plans.

2. Advancements in Genomic Technologies: The rapid advancement of genomic technologies, particularly next-generation sequencing, has revolutionized the development of companion diagnostics, allowing for more precise patient stratification.

3. Regulatory Support: Regulatory bodies, such as the FDA, have increasingly recognized the importance of companion diagnostics, leading to more streamlined approval processes and encouraging investment in this sector.

4. Growing Oncology Market: With cancer being one of the leading causes of death globally, the demand for effective targeted therapies and companion diagnostics in oncology is a significant growth driver.

Future Outlook

The companion diagnostics market is expected to continue its upward trajectory, driven by innovation and increasing collaboration between diagnostic companies and pharmaceutical firms. The emergence of digital health technologies and artificial intelligence in diagnostics may further enhance market potential.

By 2032, the landscape of companion diagnostics will likely be characterized by:

- Greater Integration with Therapeutics: As more targeted therapies emerge; companion diagnostics will become integral to treatment protocols.

- Increased Adoption in Emerging Markets: The Asia-Pacific region will play a crucial role in the market's expansion, supported by growing healthcare investments.

- Focus on Multi-Omics Approaches: The integration of genomics, proteomics, and metabolomics in companion diagnostics will enable more comprehensive patient assessments.

Read Companion Diagnostics Market Report Today - https://www.skyquestt.com/report/companion-diagnostics-market

[market-insider]

U.S. Point-of-Care Molecular Diagnostics: Adoption Trends, Regulatory Landscape, Market Potential

The U.S. point-of-care molecular diagnostics market size was estimated at USD 3.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 1.7% from 2024 to 2030. The growth of the market is driven by rise in end-user awareness, along with the increased efficiency of the testing methods and favorability for non-laboratory testing. For instance, in the U.S., approximately 1% infants are diagnosed with congenital heart diseases (CHDs) every year. However, advancements in prenatal testing have led to rapid detection of genetic biomarkers in embryos, thus leading to early diagnosis of CHDs and other genetic disorders.

Market Concentration & Characteristics

Degree of Innovation: Market growth stage is low, and pace of market growth is accelerating. The U.S. point-of-care molecular diagnostics market is characterized by a moderate-to-high degree of innovation owing to the advancements in technology, including the introduction of next-generation sequencing (NGS)-friendly applications. Previously, POC testing has seen barriers in NGS testing, and market players as well as academic institutions have focused on relentless research and development efforts to overcome these.

Players in the point-of-care molecular diagnostics market leverage market strategies such as mergers, acquisitions, collaborations, and partnerships to promote reach of their offerings and increase their product capabilities in the region. For instance, in 2022, Bio-Rad Laboratories acquires Curiosity Diagnostics, integrating Curiosity’s rapid PCR system, PCR|ONE, to expand its presence in near-patient molecular diagnostics labs.

Key U.S. Point-of-Care Molecular Diagnostics Company Insights

Some of the key players operating in the U.S. point-of-care molecular diagnostics market include Abbott Laboratories; QIAGEN; F. Hoffman-La Roche Ltd; bioMerieux; and BD. Numerous key players are undertaking strategic initiatives such as expansion, product introductions, mergers, and acquisitions, while also focusing on increasing product reach in the U.S. Several market participants are investing in research and development initiatives, making the market susceptible to further growth. For More Details or Sample Copy please visit link @:U.S. Point-of-Care Molecular Diagnostics Market

[hotzimbabwejobs]

Job Opportunity: Technician Biotechnology Platform (2 Posts) at the University of Zimbabwe! - March 2025

The University of Zimbabwe’s Faculty of Veterinary Sciences, Department of Veterinary Biosciences, is seeking two skilled Technicians to run their Biotechnology Platform laboratories! If you have a background in chemistry, biochemistry, biological sciences, or biotechnology, and a passion for molecular diagnostics and bioengineering, this is a great opportunity for you. About the Role: As a…

[industryexperts]

(via Global Molecular Diagnostics Market Size, Outlook 2024-2030)  Global Molecular Diagnostics market size is estimated at US$18 billion in 2024 and projected to post a CAGR of 10% between 2024 and 2030 to reach US$31.7 billion in 2030. The molecular diagnostics market is growing rapidly, driven by a growing need for faster and more accurate disease detection.

[idealfertilityivf]

At Ideal Fertility, we offer advanced Molecular Diagnostics through our state-of-the-art Real-Time PCR technology, which provides precise and timely results for a variety of infectious diseases. Our fully-equipped molecular biology lab specializes in the detection of high-risk conditions like Human Papilloma Virus (HPV), a leading cause of cervical cancer, and Mycobacterium tuberculosis (MTB), the bacteria responsible for tuberculosis. We also provide rapid diagnostics for tropical diseases such as Dengue, Chikungunya, and H1N1, along with comprehensive tests for HIV and Hepatitis B. Our CE-IVD validated kits ensure the highest standards of accuracy and reliability, enabling early detection and swift, effective treatment.

For more details, visit - https://idealfertility.com/services/molecular-diagnostics/

[rameshindustryarc]

𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬: 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞-IndustryARC™

The global biomarkers market size was estimated at USD 81.04 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 13.36% from 2024 to 2030.

📚 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞

#Genomic #biomarkers are Deoxyribonucleic acid (#DNA) and Ribonucleic acid (#RNA) characteristics used as disease characterization, an indicator of #diagnosis, and therapy selection. These biomarkers reflect #biological and pathogenic processes and response to therapeutic or other intervention.

The use of biomarkers in infectious disease diagnosis is anticipated to become increasingly common in the upcoming years. For instance, as per Frontiers in #Microbiology in 2020 , potential #MicroRNA-based biomarkers have been identified for the diagnosis of infections such as influenza infections, rhinoviruses, HIV, tuberculosis, malaria, Ebola, and Hendra virus. These are aimed at facilitating early onset of infectious diseases. Biomarkers are also under study for the diagnosis of SARS-CoV-2.

[texanshealthandwellnesscenter]

What is Ancillary Testing? Understanding Its Importance in Diagnostic and Medical Testing in Texas

Discover the importance of ancillary testing in Texas healthcare. Learn about its role in diagnostics, lab services, and preventive care.

[athenese-dx]

WE ARE #HIRING!

Join our team!

Apply Now → https://athenesedx.com/career/

Interested candidates kindly mail us at hr2@athenesedx.com & amit@athenesedx.com

#AtheneseDx #IVD #SalesManager #MolecularDiagnostics #Sales #Kolkata #Mumbai #Marketing #Molecular #MolecularBiology #MolecularResearch #Biochemistry #ClinicalChemistry #ClinicalLaboratory #Instruments #Pathology #LifeScience #LifeScienceJobs #IVDjobs #Precision #India #Maharashtra #WestBengal #SalesTeam #SalesJobs #HiringAlert

[marketingreportz]

Real-time PCR Market - Forecast(2024 - 2030)

𝐑𝐞𝐚𝐥-𝐓𝐢𝐦𝐞 𝐏𝐂𝐑: 𝐄𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐓𝐨𝐨𝐥 𝐟𝐨𝐫 𝐌𝐨𝐝𝐞𝐫𝐧 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐄𝐱𝐩𝐥𝐚𝐢𝐧𝐞𝐝

The global real-time PCR (qPCR) market is experiencing significant growth, driven by several key factors. The market, valued at $22.03 billion in 2024, is projected to reach $27.78 billion by 2028. This growth is largely due to the increasing prevalence of infectious diseases, the rise of cancer diagnostics, and expanding research in genomics.

The method that creates multiple copies of a particular DNA region in vitro uses the polymerase chain reaction. The technique relies on a DNA polymerase known as TAQ polymerase, which is thermostable. Thermus aquaticus is used to produce this polymerase. They occupy hot springs and hydrothermal vents. The target region to be reproduced is produced in large numbers by the PCR reaction, which involves repeat cycles at a range of temperatures.

Real-time PCR systems are laboratory instruments used to increase the number of copies of specific DNA segments. The rising prevalence of chronic and infectious diseases is driving the growth of the market for real-time polymerase chain reaction (PCR). Furthermore, forensics, diagnostics, and proteomics research advancements are creating potential growth opportunities for the real-time polymerase chain reaction (PCR) market.

📚Inquiry Before Buying :https://www.industryarc.com/reports/request-quote?id=503967&utm_source=Medium&utm_medium=Referral&utm_campaign=Deva

The polymerase chain reaction (PCR) has been used and shown to be effective in detecting minute amounts of a wide range of infectious diseases. The best conditions for amplification vary depending on the organisms of interest. PCR was used as a rapid and sensitive method for detecting infectious agents, and three assay systems were developed, one for the amplification of human T cell leukaemia virus type I, one for Mycobacterium tuberculosis, and one for Mycoplasma pneumoniae. These all factors will propel the market.

The increased use of the polymerase chain reaction for cancer diagnosis is expected to drive market growth in the coming years. All of these factors are responsible for creating a greater demand for this technique in the coming years, research and development activities for providing innovative molecular biology and forensic science as there has been a great demand for genetic engineering as well as personalized medicines.

📚Schedule a Call :https://connect.industryarc.com/lite/schedule-a-call-with-our-sales-expert?utm_source=Medium&utm_medium=Referral&utm_campaign=Deva

The global real-time PCR (qPCR) market is experiencing significant growth, driven by several key factors. The market, valued at $22.03 billion in 2024, is projected to reach $27.78 billion by 2028. This growth is largely due to the increasing prevalence of infectious diseases, the rise of cancer diagnostics, and expanding research in genomics. Real-time PCR remains a vital tool in healthcare, pharmaceuticals, and biotechnology for applications such as early disease detection, personalized medicine, and molecular diagnostics​

COVID-19 had a substantial impact on the PCR market, as demand for reliable diagnostic tools surged. The pandemic underscored the importance of real-time PCR for detecting viral infections like SARS-CoV-2, making it an essential part of disease management worldwide. This trend continues to fuel demand, especially as the technology evolves with innovations like digital PCR and multiplex assays

Buy Now: https://www.industryarc.com/buynow?id=503967&utm_source=Medium&utm_medium=Referral&utm_campaign=Deva

Regionally, North America dominates the market due to its strong healthcare infrastructure and high prevalence of diseases like hepatitis and HIV. However, the Asia-Pacific region is expected to see the fastest growth, with rising patient awareness and investments in healthcare across countries like China, Japan, 

More about Real-time PCR Market report click here 

[market-insider]

In Vitro Diagnostics Market Growth Report: Size, Share & Future Trends

The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

In Vitro Diagnostics Market Report Highlights

Molecular diagnostics is anticipated to grow at the fastest CAGR from 2024 to 2030 owing to the rising adoption and usage rate

Reagents held the largest market share owing to the surge in demand for genetic testing and enhanced availability of technologically advanced diagnostic tests in lower and middle-income countries with unmet clinical needs

The infectious diseases application segment held the largest market share owing to the large volume of testing for infectious diseases globally

North America dominated the global market in 2023 owing to the high demand for novel technologies, a large pool of key players, high prevalence of diseases, and advanced healthcare infrastructure

For More Details or Sample Copy please visit link @:In Vitro Diagnostics Market Report

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

[symbiosisonlinepublishing]

𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧: Biosensors are analytical devices that combine a biological component (such as enzymes, antibodies, or cells) with a physicochemical detector to detect the presence of a specific biological molecule or analyte. 𝐂𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭𝐬: A typical biosensor consists of a bioreceptor (the biological component), a transducer (which converts the biological response into a measurable signal), and an interface for data processing and display.

Visit @ https://symbiosisonlinepublishing.com/biosensors-biomarkers-diagnostics/

[research-masters]

Fluorescence In Situ Hybridization (FISH) Imaging Systems Market Forecast 2024 to 2032

Fluorescence in situ hybridization (FISH) imaging systems are used to visualize and analyze specific DNA or RNA sequences within cells or tissues. It is a molecular cytogenetic technique that allows researchers and clinicians to study the spatial organization and distribution of genetic material in cells.

The Fluorescence In Situ Hybridization (FISH) Imaging Systems Market was valued at USD 803.23 Million in 2022 and is expected to register CAGR of 4.79% by 2032.

Factors such as increasing prevalence of genetic disorders, rapid advancements in imaging technologies, rising research and development activities, and growing awareness about early detection and diagnostics are expected to drive global market growth during the forecast period.

Get a Free Sample Copy